Eris Lifesciences Limited — PPTs, 04-02-2025: Investor Presentation

**Financial Highlights:** Eris Lifesciences reported a 50% year-over-year increase in consolidated operating revenue for Q3 FY25, reaching INR 727 crore, with a similar 50% growth for the first nine months, totaling INR 2,188 crore. EBITDA for Q3 improved by 43% to INR 250 crore, while the nine-month figure surged by 45% to INR 765 crore. Despite a decline in gross margin to 75.7% from 81.7% due to shifts in the product mix, fixed expenses as a percentage of revenue fell significantly, underpinning improved profitability.

**Strategic Initiatives and Growth Drivers:** The launch of innovative product combinations, particularly in the SGLT2 space, is enhancing market presence. A strategic partnership for Semaglutide positions Eris to capitalize on the growing GLP-1 market segment. Future expansions at the Bhopal facility aim to optimize insulin production capabilities.

**Business Developments:** Acquisitions of Swiss and Biocon assets are anticipated to yield higher EPS growth beyond FY26 due to operational synergies and margin enhancement.

**Market Position and Competitive Advantage:** Eris maintains a strong foothold in the diabetes treatment sector, ranking among the top companies by prescription volume and possessing substantial market share in insulins.

**Investor Implications:** These developments indicate a positive outlook for Eris, with effective debt reduction strategies and a projected EPS inflection point starting FY26, driven by increased operational efficiency and market demand.